share_log

Resverlogix Announces Publication of Its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Resverlogix Announces Publication of Its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Resverlogix宣布发表其关于Apabetalone潜在治疗益处的第40篇科学期刊文章
newsfile ·  01/11 20:15

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation," by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetalone's potential therapeutic benefits.

艾伯塔省卡尔加里--(Newsfile Corp.,2024年1月11日)——Resverlogix Corp.(多伦多证券交易所股票代码:RVX)(“Resverlogix”,“公司”)今天宣布发表一篇题为” 的文章BET 抑制剂 apabetalone 可降低体外和小鼠全身性炎症模型中神经内皮促炎的激活,“由西尔维亚·瓦西亚克博士及其同事在《转化神经科学》杂志上撰写。本出版物标志着 40第四 由Resverlogix研究人员发表的关于阿帕贝塔隆潜在治疗益处的同行评审科学期刊文章。

Apabetalone's Publication Record:

Apabetalone的出版记录:

  • Articles on apabetalone have been published in some of the world's most prestigious scientific journals, including: Nature, Science, Cell, the Journal of the American Medical Association, Cardiovascular Diabetology and the Clinical Journal of the American Society of Nephrologists

  • Resverlogix researchers and our collaborators have published 40 articles on apabetalone in scientific journals, and including work by third-party researchers, there are more than 100 articles on apabetalone in the academic literature

  • This body of work presents evidence of apabetalone's potential in the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and vascular cognitive impairment, as well as rare diseases such as pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, and Fabry's disease

  • The publications also cover a wide spectrum of topics from investigations of apabetalone's mechanism of action at a molecular level, to reports on large-scale clinical trials with thousands of participants

  • 有关阿帕贝塔隆的文章已发表在一些世界上最负盛名的科学期刊上,包括:《自然》、《科学》、《细胞》、《美国医学会杂志》、《心血管糖尿病学》和《美国肾脏科医生学会临床杂志》

  • Resverlogix的研究人员和我们的合作者已经在科学期刊上发表了40篇关于阿帕贝他隆的文章,包括第三方研究人员的研究,学术文献中有100多篇关于阿帕贝他隆的文章

  • 这一系列研究为阿帕贝他酮在治疗心血管疾病、糖尿病、COVID-19后疾病、慢性肾脏病和血管认知障碍以及肺动脉高压、面肩肱肌营养不良症和法布里氏病等罕见疾病方面的潜力提供了证据

  • 这些出版物还涵盖了广泛的主题,从分子层面研究阿帕贝他酮的作用机制到有数千名参与者参与的大规模临床试验报告

"We are very proud of our publication record on apabetalone," said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. "Thanks to the dedicated work of our researchers, we have learned an incredible amount about this drug; how it works, why it's safe, and how it can potentially benefit people suffering from chronic disease."

Resverlogix首席科学官埃维琳娜·库利科夫斯基博士说:“我们为我们在apabetalone上的出版记录感到非常自豪。”“多亏了我们研究人员的敬业工作,我们已经学到了很多关于这种药物的知识;它的工作原理,为什么安全,以及它如何可能使慢性病患者受益。”

"The depth and breadth of our knowledge of apabetalone is on full display in the forty scientific articles that we have published to date," said Donald McCaffrey, President and CEO at Resverlogix. "We firmly believe that apabetalone will help chronic disease patients, we have published an extraordinary amount of evidence that supports our belief, and we are looking forward to conclusively demonstrating it in our upcoming, Phase 3, cardiovascular disease trial, BETonMACE2."

Resverlogix总裁兼首席执行官唐纳德·麦卡弗里表示:“我们迄今为止发表的四十篇科学文章充分体现了我们对阿帕贝塔隆知识的深度和广度。”“我们坚信阿帕贝他隆将帮助慢性病患者,我们已经发布了大量支持我们信念的证据,我们期待在即将到来的心血管疾病3期试验BetonMace2中最终证明这一点。”

Highlights from our Latest Publication:

我们最新出版物的亮点:

  • Inflammation in the small blood vessels of the brain is linked to cognitive impairment and decline

  • Using cultured human brain endothelial cells and monocytes, the authors studied apabetalone's effects on inflammation in these small vessels

  • They found that apabetalone treatment reduced the production of pro-inflammatory molecules and cell-cell interactions

  • Their findings were confirmed in a mouse model of brain inflammation, where apabetalone decreased the expression of pro-inflammatory genes

  • By lessening inflammation in the small blood vessels of the brain, apabetalone may help prevent or treat vascular cognitive impairment

  • 大脑小血管发炎与认知障碍和认知能力下降有关

  • 作者使用培养的人脑内皮细胞和单核细胞,研究了apabetalone对这些小血管炎症的影响

  • 他们发现阿巴贝塔隆治疗减少了促炎分子的产生和细胞间的相互作用

  • 他们的发现得到了脑部炎症小鼠模型的证实,在该模型中,阿帕贝他隆降低了促炎基因的表达

  • 通过减轻大脑小血管的炎症,阿帕贝他隆可能有助于预防或治疗血管认知障碍

Our latest article is published online HERE.

我们的最新文章在这里在线发布。

About Apabetalone

关于 Apabetalone

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.

Apabetalone(RVX-208)是同类首创的小分子候选治疗药物,具有表观遗传学作用机制。它是一种BD2(溴结构域)选择性BET(溴结构域和外末端)抑制剂,通过调节致病基因的表达来预防和治疗疾病。

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data.

由于BET蛋白在人体中的广泛作用,apabetalone可以同时靶向多种与疾病相关的生物过程,这是一种治疗慢性病的新方法。Apabetalone是同类药物中唯一一种长期给药耐受性良好的药物,在多项人体临床试验中都有良好的安全记录,共有超过4200名患者年的安全数据。

Cardiology:

心脏病学:

Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Apabetalone是同类药物中第一种因主要心血管适应症获得美国食品药品监督管理局突破性疗法称号的疗法。在此之前,其3期研究BetonMace取得了开创性的发现,该研究表明,在同时患有2型糖尿病的高危心血管疾病患者中,阿帕贝他酮可以预防重大的心脏不良事件。

About Resverlogix

关于 Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立于2001年,是一家总部位于卡尔加里的后期生物技术公司,也是表观遗传学领域的全球领导者,目标是开发一流的疗法,使慢性病患者受益。

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

Resverlogix正在开发一类新的表观遗传学疗法,旨在调节致病基因的表达。我们的目标是通过将因心血管疾病等严重疾病而改变的生物学功能恢复到更健康的状态来改善患者的生活。

The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

该公司的临床项目侧重于评估用于治疗心血管疾病、相关合并症和 COVID-19 后疾病的主要表观遗传学候选药物阿帕贝塔隆。

Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Resverlogix已与全球生命科学行业下一代商业服务的先驱EVERSANA合作,以支持加拿大和美国治疗心血管疾病、COVID-19 后疾病和肺动脉高压的阿帕贝他隆的快速商业化。

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix普通股在多伦多证券交易所(多伦多证券交易所股票代码:RVX)上市。

Follow us: Twitter: @Resverlogix_RVX. LinkedIn: .

关注我们:推特:@Resverlogix_RVX。领英:。

Forward-Looking Statements:

前瞻性陈述:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, diabetes, chronic kidney disease, vascular cognitive impairment, COVID-19, post COVID-19 conditions, pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, Fabry's disease, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新闻稿可能包含适用的加拿大证券立法所定义的某些前瞻性信息,这些信息并非基于历史事实,包括但不限于包含 “相信”、“预期”、“计划”、“打算”、“将”、“应该”、“期望”、“继续”、“估计”、“预测” 和其他类似表述的陈述。特别是,本新闻稿包括与apabetalone在心血管疾病,糖尿病,慢性肾脏病患者治疗中的潜在作用有关的前瞻性信息, 血管认知障碍,COVID-19,COVID-19 后病症, 肺动脉高压、面肩肱肌营养不良症、法布里氏病、相关合并症和其他慢性疾病。我们的实际业绩、事件或事态发展可能与这些前瞻性陈述所表达或暗示的业绩、事件或事态发展存在重大差异。我们无法保证任何事件或期望会发生或实现。就其性质而言,前瞻性陈述受许多假设和风险因素的约束,包括我们的年度信息表和最新的MD&A中讨论的假设和风险因素,这些假设和风险因素以引用方式纳入此处,可通过SEDAR获得,网址为。本新闻稿中包含的前瞻性陈述受本警示声明的明确限制,并自本新闻稿发布之日起作出。除非法律要求,否则公司无意更新或修改任何前瞻性陈述,也没有义务或责任更新或修改任何前瞻性陈述,无论是由于新信息、未来事件还是其他原因。

For further information please contact:

欲了解更多信息,请联系:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

投资者关系
电子邮件:ir@resverlogix.com
电话:403-254-9252

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发